EP1572103A4 - Verwendungen von il-6-antagonisten gegen die angiogenese - Google Patents

Verwendungen von il-6-antagonisten gegen die angiogenese

Info

Publication number
EP1572103A4
EP1572103A4 EP03783264A EP03783264A EP1572103A4 EP 1572103 A4 EP1572103 A4 EP 1572103A4 EP 03783264 A EP03783264 A EP 03783264A EP 03783264 A EP03783264 A EP 03783264A EP 1572103 A4 EP1572103 A4 EP 1572103A4
Authority
EP
European Patent Office
Prior art keywords
angiogenic
antagonists
angiogenic uses
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03783264A
Other languages
English (en)
French (fr)
Other versions
EP1572103A2 (de
Inventor
Mohit Trikha
Zhao Zhou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Biotech Inc
Original Assignee
Centocor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centocor Inc filed Critical Centocor Inc
Publication of EP1572103A2 publication Critical patent/EP1572103A2/de
Publication of EP1572103A4 publication Critical patent/EP1572103A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP03783264A 2002-11-15 2003-11-10 Verwendungen von il-6-antagonisten gegen die angiogenese Withdrawn EP1572103A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42690102P 2002-11-15 2002-11-15
US426901P 2002-11-15
PCT/US2003/035651 WO2004045507A2 (en) 2002-11-15 2003-11-10 Anti-angiogenic uses of il-6 antagonists

Publications (2)

Publication Number Publication Date
EP1572103A2 EP1572103A2 (de) 2005-09-14
EP1572103A4 true EP1572103A4 (de) 2008-02-13

Family

ID=32326451

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03783264A Withdrawn EP1572103A4 (de) 2002-11-15 2003-11-10 Verwendungen von il-6-antagonisten gegen die angiogenese

Country Status (5)

Country Link
EP (1) EP1572103A4 (de)
JP (1) JP2006516957A (de)
AU (1) AU2003290682A1 (de)
CA (1) CA2506230A1 (de)
WO (1) WO2004045507A2 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2866566A1 (fr) * 2004-02-20 2005-08-26 Galderma Res & Dev Utilisation d'un inhibiteur de la secretion d'il-5,il-6 et/ou il-10 pour le traitement de la rosacee
IL163856A0 (en) * 2004-09-01 2005-12-18 Applied Research Systems Use of IL-6 in vascular complications
RU2446826C2 (ru) 2005-10-14 2012-04-10 Фукуока Юниверсити Агенты для подавления повреждения трансплантированных островков после трансплантации островков
AR058135A1 (es) 2005-10-21 2008-01-23 Chugai Pharmaceutical Co Ltd Agentes para el tratamiento de cardiopatias
AR057582A1 (es) 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
WO2007076927A1 (en) 2005-12-30 2007-07-12 Merck Patent Gmbh Anti-il-6 antibodies preventing the binding of il-6 complexed with il-6ralpha to gp130
CA2637917C (en) * 2006-01-27 2015-11-24 Keio University Therapeutic agents for diseases involving choroidal neovascularization
EP2025346B1 (de) 2006-04-07 2016-08-10 Osaka University Mittel zur förderung der muskelregeneration
MX2009001110A (es) 2006-08-03 2009-05-11 Vaccinex Inc Anticuerpos monoclonales anti-il-6 y usos de los mismos.
TW200831528A (en) 2006-11-30 2008-08-01 Astrazeneca Ab Compounds
WO2008090901A1 (ja) 2007-01-23 2008-07-31 Shinshu University 慢性拒絶反応抑制剤
EP2174667B1 (de) 2007-07-26 2017-01-04 Osaka University Mittel zur behandlung von augenentzündungen mit interleukin-6-rezeptorhemmer als wirkstoff
CA2706549A1 (en) * 2007-11-15 2009-05-22 Chugai Seiyaku Kabushiki Kaisha Monoclonal antibody capable of binding to anexelekto, and use thereof
TWI528973B (zh) 2008-06-05 2016-04-11 Chugai Pharmaceutical Co Ltd Nerve infiltration inhibitor
US8188235B2 (en) 2008-06-18 2012-05-29 Pfizer Inc. Antibodies to IL-6 and their uses
EP2432480B1 (de) * 2009-05-18 2021-05-05 The University of Hong Kong Zusammensetzungen und verfahren zur behandlung entzündlicher arthritis
AU2010278067B2 (en) * 2009-07-31 2016-10-27 Shin Maeda Cancer metastasis inhibitor
JP6051049B2 (ja) 2010-05-28 2016-12-21 中外製薬株式会社 抗腫瘍ｔ細胞応答増強剤
BR112015010360A8 (pt) * 2012-11-08 2018-01-16 Eleven Biotherapeutics Inc antagonistas de il-6 e utilização dos mesmos.
EP2898896A1 (de) 2014-01-22 2015-07-29 Université Pierre et Marie Curie (Paris 6) Mittel zur Verwendung bei der Behandlung von Netzhautentzündung
CN106102766A (zh) * 2014-01-22 2016-11-09 皮埃尔与玛丽·居里大学 - 巴黎第六大学 用于治疗视网膜炎症的试剂
PT3215530T (pt) * 2014-11-07 2019-11-21 Sesen Bio Inc Anticorpos de il-6 melhorados
EP3419599A4 (de) 2016-02-23 2019-09-11 Sesen Bio, Inc. Il-6-antagonistformulierungen und verwendung davon
KR20200012823A (ko) 2017-02-01 2020-02-05 예일 유니버시티 이뇨제 내성의 치료
EP3620531A4 (de) 2017-05-02 2021-03-17 National Center of Neurology and Psychiatry Verfahren zur vorhersage und beurteilung der therapeutischen wirkung bei erkrankungen im zusammenhang mit il-6 und neutrophilen
EP3698808B1 (de) 2017-10-20 2025-01-01 Hyogo College Of Medicine Anti-il-6 rezeptorantikörper enthaltende medizinische zusammensetzung zur verhinderung von postoperativer adhäsion
CA3087699A1 (en) 2018-01-05 2019-07-11 Corvidia Therapeutics, Inc. Methods for treating il-6 mediated inflammation without immunosuppression
WO2019151418A1 (ja) 2018-01-31 2019-08-08 元一 加藤 Ｉｌ－６阻害剤を含有する喘息の治療剤
IL287220B2 (en) 2019-04-17 2026-03-01 Univ Hiroshima A therapeutic agent for urological cancer characterized by administering an IL-6 inhibitor in combination with a CCR2 inhibitor

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998036061A2 (en) * 1997-02-13 1998-08-20 The Victoria University Of Manchester Reducing fibrosis and/or scarring by inhibiting interleukin-6 receptor-mediated activity
WO2000078815A1 (en) * 1999-06-24 2000-12-28 Applied Molecular Evolution ANTI-αvβ3? RECOMBINANT HUMAN ANTIBODIES, NUCLEIC ACIDS ENCODING SAME AND METHODS OF USE

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0800829B2 (de) * 1994-12-29 2012-07-25 Chugai Seiyaku Kabushiki Kaisha Verwendung eines pm-1 antikörpers oder eines mh 166 antikörpers zur verstärkung des anti-tumor-effektes von cisplatin oder carboplatin

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998036061A2 (en) * 1997-02-13 1998-08-20 The Victoria University Of Manchester Reducing fibrosis and/or scarring by inhibiting interleukin-6 receptor-mediated activity
WO2000078815A1 (en) * 1999-06-24 2000-12-28 Applied Molecular Evolution ANTI-αvβ3? RECOMBINANT HUMAN ANTIBODIES, NUCLEIC ACIDS ENCODING SAME AND METHODS OF USE

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
D. WENDLING ET AL.: "Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody.", JOURNAL OF RHEUMATOLOGY, vol. 20, February 1993 (1993-02-01), pages 259 - 262, XP000972960 *
H. VAN ZAANEN ET AL.: "Chimaeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a phase I dose-escalating study.", BRITISH JOURNAL OF HAEMATOLOGY, vol. 102, 1998, pages 783 - 790, XP002986057 *
J-Y. BLAY ET AL.: "Role of interleukin-6 in the paraneoplastic inflammatory syndrome associated with renal-cell carcinoma.", INTERNATIONAL JOURNAL OF CANCER, vol. 72, 1997, pages 424 - 430, XP002461200 *
K. YOSHIZAKI ET AL.: "Therapy of rheumatoid arthritis by blocking IL-6 signal transduction with a humanized anti-IL-6 receptor antibody.", SPRINGER SEMINARS IN IMMUNOPATHOLOGY, vol. 20, 1998, pages 247 - 259, XP001069950 *
P. SMITH ET AL.: "Anti-interleukin-6 monoclonal antibody induces regression of human prostate cancer xenografts in nude mice.", PROSTATE, vol. 48, 2001, pages 47 - 53, XP003012696 *

Also Published As

Publication number Publication date
EP1572103A2 (de) 2005-09-14
AU2003290682A1 (en) 2004-06-15
WO2004045507A2 (en) 2004-06-03
CA2506230A1 (en) 2004-06-03
WO2004045507A3 (en) 2006-01-26
JP2006516957A (ja) 2006-07-13

Similar Documents

Publication Publication Date Title
EP1572103A4 (de) Verwendungen von il-6-antagonisten gegen die angiogenese
IL165841A0 (en) Mchir antagonists
GB0404124D0 (en) Antagonists of GIP
PL378134A1 (pl) Nowe pochodne bicykliczne i kompozycje farmaceutyczne zawierające pochodne bicykliczne
ZA200605348B (en) Solid forms of anti-EGFR-antibodies
IL181720A0 (en) Bicyclic amides as kinase inhibitors
PT1619180E (pt) Antagonista de casr
IL175084A0 (en) Antagonists of the bradykinin b1 receptor
IL163939A0 (en) Nk1 antagonists
TWI349670B (en) Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones
ZA200409686B (en) Bicyclic 6-aklylidene-penems as ?-lactamases inhibitors
AU2003291959A8 (en) Novel glucagon antagonists
IL165727A0 (en) Chemokine antagonists
AU2003260072A8 (en) Antagonists of chemokine receptors
ZA200700650B (en) Bicyclic amides as kinase inhibitors
EP1651643A4 (de) Bicyclische verbindungen und zusammensetzungen als pdf-inhibitoren
GB2402141B (en) Building block
AU2003223329A8 (en) Antagonists of rf-amide neuropeptides
GB2389594B (en) Building component
GB2438806B (en) Building
IL175151A0 (en) Bicyclic pyrazolone cytokine inhibitors
GB0301663D0 (en) Scaffolding
AU2003264036A8 (en) Pi3k antagonists as radiosensitizers
GB0317503D0 (en) Building components
TW560584U (en) Improvement of screw

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050614

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

PUAK Availability of information related to the publication of the international search report

Free format text: ORIGINAL CODE: 0009015

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/395 20060101AFI20060405BHEP

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 27/00 20060101ALI20071218BHEP

Ipc: A61P 35/04 20060101ALI20071218BHEP

Ipc: A61P 35/00 20060101ALI20071218BHEP

Ipc: A61K 39/395 20060101AFI20060405BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20080111

17Q First examination report despatched

Effective date: 20080806

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20081217